a public good project by the
Synthesis
Company
of California

© 2026

Tadashi Namisaki | doi.page

0 works0 citations0 h-index

Tadashi Namisaki

Nara Medical University Hospital(JP)Nara Medical University(JP)

Publications by Year

Research Areas

Liver Disease Diagnosis and Treatment, Liver Disease and Transplantation, Liver Diseases and Immunity, Hepatocellular Carcinoma Treatment and Prognosis, Pediatric Hepatobiliary Diseases and Treatments

Most-Cited Works

→ The Effect of Inflammatory Cytokines in Alcoholic Liver Disease(2013)250 cited
→ Sodium glucose cotransporter 2 inhibitor canagliflozin attenuates liver cancer cell growth and angiogenic activity by inhibiting glucose uptake(2017)245 cited
→ Tissue inhibitor of metalloproteinases-1 attenuates spontaneous liver fibrosis resolution in the transgenic mouse(2002)217 cited
→ Plasma Endotoxin and Serum Cytokine Levels in Patients With Alcoholic Hepatitis: Relation to Severity of Liver Disturbance(2000)183 cited
→ Imatinib mesylate (STI-571) attenuates liver fibrosis development in rats(2004)146 cited
→ Leptin‐mediated neovascularization is a prerequisite for progression of nonalcoholic steatohepatitis in rats†(2006)143 cited

→ Genome-Wide Association Study Identifies TLL1 Variant Associated With Development of Hepatocellular Carcinoma After Eradication of Hepatitis C Virus Infection(2017)

138 cited

→ Dipeptidyl peptidase-4 inhibitor attenuates hepatic fibrosis via suppression of activated hepatic stellate cell in rats(2013)130 cited

→ Bezafibrate Improves GLOBE and UK‐PBC Scores and Long‐Term Outcomes in Patients With Primary Biliary Cholangitis(2019)111 cited

→ Tissue inhibitor of metalloproteinases‐1 (TIMP‐1) inhibits tumor growth and angiogenesis in the TIMP‐1 transgenic mouse model(2003)110 cited